AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00703820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: See Detailed Description
Study NCT02457650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 TCR-transduced T cells
Description: Modified cells will be infused IV over 30 minutes.
Study NCT02651324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02651324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03598049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: densah burs osseo densification drills
Description: osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
Study NCT03598049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgical burs drilling
Description: conventional implant osteotomy site drilling with implant surgical kit
Study NCT02986633 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Study NCT03310359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Description: The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
Study NCT03310359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pill
Study NCT01898286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277®
Description: 1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
Study NCT01274598 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)
Description: 1x10\^10 CFU by mouth twice daily for 28 days
Study NCT02659813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed brace
Study NCT04899726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectoscope (P201630551)
Description: Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
Study NCT00633763 — intervention group
Intervention type: DRUG
Intervention: 18F-fallypride
Description: Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
Study NCT00633763 — intervention group
Intervention type: DRUG
Intervention: 18F-fallypride
Description: I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
Study NCT04532125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Subjects treated with ARGX-117
Study NCT01785108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Study NCT04532125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects treated with placebo
Study NCT04532125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117 + rHuPH20
Description: Subjects treated with ARGX-117 + rHuPH20
Study NCT04532125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo + rHuPH20
Description: Subjects treated with placebo + rHuPH20
Study NCT04532125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117 PH20 SC
Description: Subjects treated with ARGX-117 PH20 SC
Study NCT04532125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC
Description: Subjects treated with placebo PH20 SC
Study NCT00703820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: See Detailed Description
Study NCT00703820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: See Detailed Description
Study NCT00703820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
Study NCT03380611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wakame
Description: Consumption of 4.8 grams wakame per day for 17 days
Study NCT03380611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Consumption of 4.8 grams spirulina per day for 17 days
Study NCT03380611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Consumption of microcrystalline cellulose for 17 days
Study NCT01404598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 bid
Description: naproxcinod 750 bid
Study NCT01404598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 3000 mg od
Description: naproxcinod 3000 mg od
Study NCT01404598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 500 mg bid
Description: naproxen 500 mg bid
Study NCT02621086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellodextrin
Description: Gastrointestinal tolerability of single ascending doses of Cellodextrins
Study NCT03639896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
Study NCT03639896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
Study NCT03172234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral amantadine sulfate
Description: In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
Study NCT03172234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral gabapentin
Description: In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
Study NCT03172234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
Study NCT01522573 — intervention group
Intervention type: PROCEDURE
Intervention: EUS guided ERCP
Description: Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
Study NCT01176708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose
Description: 50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
Study NCT01176708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous glucose
Description: 1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
Study NCT01785108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT01785108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Study NCT00228943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Description: L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
Study NCT00228943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Half-strength tryptophan depletion (Control)
Description: L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
Study NCT01597466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural catheter placement
Description: Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
Study NCT01597466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural catheter placement
Description: Epidural space is located using loss of resistance technique (saline solution)
Study NCT01020344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung volume reduction surgery
Description: Lung volume reduction surgery
Study NCT02427035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
Study NCT02427035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study NCT01730352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H. pylori triple therapy
Description: Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
Study NCT02448706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting A
Study NCT02448706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid Fitting B
Study NCT00658827 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
Study NCT01139541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social walking intervention
Description: In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
Study NCT02353858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep regional hyperthermia
Description: Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
Study NCT02353858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
Study NCT02353858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-Fluorouracil)
Description: 5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
Study NCT04684940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Study NCT00566046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Study NCT00566046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
Study NCT00938912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
Study NCT00938912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day.
Study NCT02420184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
Study NCT02420184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No CPAP
Description: Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
Study NCT02076529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron 0.3mg
Study NCT02076529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.45mg
Study NCT02076529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6mg
Study NCT03322631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.
Study NCT03322631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT02614339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
Study NCT02614339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
Study NCT03625089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom.
Study NCT03625089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom.
Study NCT00225212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2
Study NCT00683007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume resuscitation (Crystalloid)
Description: Crystalloid vs. Hypertonic Saline Solution
Study NCT00683007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume resuscitation (Hypertonic Saline Solution)
Description: Crystalloid vs. Hypertonic Saline Solution
Study NCT01463657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm® Ultra Plus
Description: Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
Study NCT01463657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002
Description: Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
Study NCT03584438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
Study NCT03584438 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study NCT00100646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 300 mg tablet taken orally daily
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
Study NCT00140426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
Study NCT00140426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stavudine
Description: Dosage dependent on weight
Study NCT00100646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Dosage dependent on weight
Study NCT00100646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies de novo antigen
Description: Vaccine injected intramuscularly
Study NCT00100646 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies de novo antigen
Description: Vaccine injected intramuscularly
Study NCT01604096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted information campaign
Description: Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians
Study NCT01674127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Study NCT01674127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02126813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: increased interventional threshold for urinary bladder catheterization (800 ml)
Study NCT02126813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current used interventional threshold for urinary bladder catheterization (500 ml)
Study NCT02126813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bladder catheter
Study NCT02126813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent bladder catheter
Study NCT00985712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Study NCT00985712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huminsulin Regular
Description: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
Study NCT00985712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HumaPen Memoir
Description: subcutaneously, daily for 24 weeks
Study NCT00985712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HumaPen Luxura
Description: subcutaneously, daily for 24 weeks